摘要
The relationship between erectile dysfunction （ED） and chronic renal failure （CRF） has been reported in several studies. This study aimed to investigate whether the chronic use of sildenafil could enhance the erectile capacity in CRF-induced rats. In addition, we assessed the effect of that treatment on certain molecules, which have been suggested to play crucial roles in erectile physiology and CRF-related ED as well. Three groups of animals were utilized： （1） age-matched control rats, （2） CRF-induced rats, （3） CRF-induced rats treated with chronic administration of sildenafil （5 mg kg^-1 p.o. for 6 weeks [treatment started after 6 weeks of CRF induction]）. At 3 months, all animals underwent cavernosal nerve stimulation （CNS） to assess erectile function. Penile tissue advanced glycation end products （AGE＇s）/5-hydroxymethyl-2-furaldehyde, malondialdehyde （MDA）, cGMP （ELISA）, inducible nitric oxide synthase （iNOS） and neuronal NOS （nNOS） （Western blot） analyses were performed in all rat groups. CRF-induced rats had a significant decrease in erectile function when compared to control rats （P 〈 0.05）. The increase in both intracavernosal pressure （ICP） and area under the curve of CRF-induced rats treated with sildenafil （Group 3） was greater than CRF-induced rats （Group 2）. Additionally, sildenafil treatment decreased AGE, MDA and iNOS levels, while it preserved nNOS and cGMP contents in CRF-induced penile tissue. Decreased AGE, MDA, iNOS and increased nNOS, cGMP levels at the sildenafil-treated group increased both ICP and Total ICP to CNS, which led to improve erectile function in CRF-induced rats. The results of the present study revealed the therapeutic effect of chronic sildenafil administration on erectile function in CRF-induced rats.
The relationship between erectile dysfunction （ED） and chronic renal failure （CRF） has been reported in several studies. This study aimed to investigate whether the chronic use of sildenafil could enhance the erectile capacity in CRF-induced rats. In addition, we assessed the effect of that treatment on certain molecules, which have been suggested to play crucial roles in erectile physiology and CRF-related ED as well. Three groups of animals were utilized： （1） age-matched control rats, （2） CRF-induced rats, （3） CRF-induced rats treated with chronic administration of sildenafil （5 mg kg^-1 p.o. for 6 weeks [treatment started after 6 weeks of CRF induction]）. At 3 months, all animals underwent cavernosal nerve stimulation （CNS） to assess erectile function. Penile tissue advanced glycation end products （AGE＇s）/5-hydroxymethyl-2-furaldehyde, malondialdehyde （MDA）, cGMP （ELISA）, inducible nitric oxide synthase （iNOS） and neuronal NOS （nNOS） （Western blot） analyses were performed in all rat groups. CRF-induced rats had a significant decrease in erectile function when compared to control rats （P 〈 0.05）. The increase in both intracavernosal pressure （ICP） and area under the curve of CRF-induced rats treated with sildenafil （Group 3） was greater than CRF-induced rats （Group 2）. Additionally, sildenafil treatment decreased AGE, MDA and iNOS levels, while it preserved nNOS and cGMP contents in CRF-induced penile tissue. Decreased AGE, MDA, iNOS and increased nNOS, cGMP levels at the sildenafil-treated group increased both ICP and Total ICP to CNS, which led to improve erectile function in CRF-induced rats. The results of the present study revealed the therapeutic effect of chronic sildenafil administration on erectile function in CRF-induced rats.
